Brivanib (Standard)
Brivanib (Standard) is the analytical standard of Brivanib. This product is intended for research and analytical applications. Brivanib (BMS-540215) is an ATP-competitive inhibitor against VEGFR2 with an IC50 of 25 nM, and has moderate potency against VEGFR-1 and FGFR-1, but >240-fold against PDGFR-β[1].
Product Specifications
CAS Number
649735-46-6
Product Name Alternative
BMS-540215 (Standard)
UNSPSC
12352005
Target
Autophagy; Reference Standards; VEGFR
Type
Reference Standards
Related Pathways
Autophagy; Others; Protein Tyrosine Kinase/RTK
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/brivanib-standard.html
Smiles
FC1=C(OC2=NC=NN3C2=C(C(OC[C@H](O)C)=C3)C)C=CC4=C1C=C(C)N4
Molecular Formula
C19H19FN4O3
Molecular Weight
370.38
References & Citations
[1]Bhide RS, et al. Discovery and preclinical studies of (R) -1- (4- (4-fluoro-2-methyl-1H-indol-5-yloxy) -5- methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy) propan- 2-ol (BMS-540215), an in vivo active potent VEGFR-2 inhibitor. J Med Chem, 2006, 49 (7), 2143-2146.|[2]Huynh H, et al. Brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth inhibition in mouse models of human hepatocellular carcinoma. Clin Cancer Res, 2008, |[3]Nakamura I, et al. Correction: Brivanib Attenuates Hepatic Fibrosis In Vivo and Stellate Cell Activation In Vitro by Inhibition of FGF, VEGF and PDGF Signaling. PLoS One. 2015 Nov 3;10 (11) :e0142355.
Shipping Conditions
Room temperature
Scientific Category
Reference Standards
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
